Matinas BioPharma Holdings, Inc.
http://www.matinasbiopharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Matinas BioPharma Holdings, Inc.
Sanofi Picks Venture Capitalist Ashrafian To Succeed Reed As R&D Head
The French drugmaker is banking on the wealth of expertise that Houman Ashrafian brings as both a scientist and biotech entrepreneur to drive forward its R&D efforts.
BioNTech Bolsters Cancer Immunotherapy Ambitions In Pact With Cash-Poor Ryvu
Deal Snapshot: German firm gets license rights to Ryvu’s STING agonist portfolio in addition to collaborating on immunomodulators. Ryvu adds need cash via upfront and equity payments from BioNTech.
AstraZeneca Buys Into COVID-19 Antibodies From Newly Launched RQ Bio
The big pharma company and its new partner both expect demand to continue for pre-exposure prophylaxis antibody therapies, for COVID-19 and beyond.
Deal Watch: Dragonfly Adds Gilead To Its List Of Big-Name Partners
AbbVie inks collaboration and option deal focused on targeted protein degradation with Plexium. Cend and Calabrius merge in an all-stock transaction.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Aquarius BioTechnologies Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice